This fact may point to evidence of an underexpression/dysfunction of α-cell-GCK in T2DM, suggesting that GCK enhancers are a promissory therapy, not merely for their effects on insulin but also for their inhibitory effects on glucagon secretion. This evidence concerns the gene INS and type 2 diabetes mellitus.